Isaflex Pain Relief Cream
Natural health product licensed in Canada
- Licence holder
- Shore Break Group LTD
- NPN or DIN-HM
- 80066634
- Status
- Active licence
- Licence date
- 27 January 2016
- Revision date
- Not provided
- Form
- Crème
- Route of administration
- Topique
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| Arnica montana Source : Arnica Montana - fleur | 1 % |
| Acide 4-aminobenzoïque, Ester d'éthyle Source : Benzocaine | 1.5 % |
Non-medicinal ingredients
Stéarate de tridécyle, Ethylhexylglycérine, Phénoxyéthanol, Extrait de gomme de Boswellia serrata, Dicaprylate/dicaprate de néopentyl glycol, Huile essentielle de verveine des Indes orientale, PEG-8, Chlorhydrate de glucosamine, Glycérine, Filtrat de fermentation de racine de radis par la bactérie Leuconostoc, Acide stéarique, Hydroxyde de sodium, Sorbate de potassium, Huile de Glycine Soja (fève de soja), Polymère croisé d'acrylates/acrylate d'alkyle en C10 à 30, Vanillyl butyl éther, Jus de feuilles d'Aloe Barbadensis, Aqua, d-alpha tocophérol, Stéarate de PEG-100, Cire d'abeille, Méthylsulfonylméthane, Benzoate de sodium, Isosorbide de diméthyle, Triéthanolamine, Acide citrique, Acide salicylique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | Not specified | Not specified |
Uses authorised in Canada
Used in Herbal Medicine to help relieve pain and/or inflammation in muscles and joints (e.g. sprains, bruises, joint pain).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. If symptoms do not improve within seven days, irritation, pain or redness persists or worsens, or swelling, rash or fever develops, consult a health care practitioner promptly.
- Effets indésirables connus
Hypersensitivity/allergy is known to occur. In such a case, discontinue use.
- Contre-indications
If allergic to benzocaine, do not use this product. If the following symptoms appear: weakness, confusion, headache, difficulty breathing and/or pale, gray or blue coloured skin, stop use and consult a health care practitioner. These symptoms may be signs of methemoglobinemia, a rare disorder, which may appear up to 2 hours after use. Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family.
Source
Official Health Canada record, licence 80066634
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.